Picture loading failed.

Anti-MIF therapeutic antibody (Pre-made Imalumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth. and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-265-1mg 1mg 3090
GMP-Bios-ab-265-10mg 10mg 21890
GMP-Bios-ab-265-100mg 100mg 148000
GMP-Bios-ab-265-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-MIF therapeutic antibody (Pre-made Imalumab biosimilar,Whole mAb)
INN Name Imalumab
TargetMIF
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI Structure6foe:HL:AB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesCytokine PharmaSciences;Baxalta;Shire;Takeda
Conditions Approvedna
Conditions ActiveColorectal cancer;Malignant ascites
Conditions DiscontinuedSolid tumours;Lupus nephritis
Development Techna